Abstract
Prediction of oncological outcomes facilitates individualized risk-adapted management for clinical stage I testicular nonseminomatous germ cell tumors (CS I NSGCTs). We investigated risk factors for relapse following orchidectomy, with particular focus on patients with active surveillance. Patients with CS I NSGCTs treated by retroperitoneal lymph node dissection (RPLND), chemotherapy, or surveillance between January 1997 and December 2009 were identified. Demographic and post-operative records were collected. Disease-specific survival and progression-free survival (PFS) rates were estimated using Kaplan–Meier analysis. Cox regression analysis was used to confirm variables that influenced disease relapse. A median follow-up period of 82 months was achieved in 89 patients, of whom 9 (8 in surveillance and 1 in chemotherapy group) had relapses. Cumulative 5-year PFS rates were 74.1, 92.3, and 100 % for the surveillance, chemotherapy, and RPLND groups, respectively (p = 0.01). The relapse rate was significantly higher in patients presented with lymphatic/vascular invasion (LVI) than in those without LVI (26.6 vs. 6.8 %, p = 0.02). In the surveillance group, a higher relapse rate was associated with history of cryptorchidism (50 vs. 13.3 %, p = 0.02) and an age older than 13 years (33.3 vs. 5.9 %, p = 0.04). On multivariate analysis, patient age (OR 1.16; p = 0.05), history of cryptorchidism (OR 0.09; p = 0.01), and LVI (OR 12.10; p = 0.01) were significantly associated with relapse during surveillance. The disease-free period is short in the patients with surveillance. LVI, patient age, and history of cryptorchidism may be used as predictors for relapse during surveillance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albers P, Albrecht W, Algaba F, et al. EAU guidelines on testicular cancer: 2011 update. Actas Urol Esp. 2012;36(3):127–45.
Choueiri TK, Stephenson AJ, et al. Management of clinical stage I nonseminomatous germ cell testicular cancer. Urol Clin N Am. 2007;34(2):137–48.
Nguyen CT, Fu AZ, Gilligan TD, et al. Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis. J Clin Oncol. 2010;28(1):119–25.
Sonneveld DJ, Koops HS, Sleijfer DT, et al. Surgery versus surveillance in stage I non-seminoma testicular cancer. Semin Surg Oncol. 1999;17(4):230–9.
Nelson JB, Chen RN, Bishoff JT, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology. 1999;54(6):1064–7.
Rassweiler JJ, Scheitlin W, Heidenreich A, et al. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective. Eur Urol. 2008;54(5):1004–15.
Shahidi M, Norman AR, Dearnaley DP, et al. Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer. 2002;95(3):520–30.
Van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007;25(28):4370–8.
Schmoll HJ, Jordan K, Huddart R, et al. Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):89–96.
Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw. 2009;7(6):672–93.
Gels ME, Hoekstra HJ, Sleijfer DT, et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol. 1995;13(5):1188–94.
Albers P, Siener R, Kliesch S, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the german testicular cancer study group trial. J Clin Oncol. 2003;21(8):1505–12.
Vergouwe Y, Steyerberg EW, Eijkemans MJ, et al. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol. 2003;21(22):4092–9.
Liu ZW, Zhou FJ, Han H, et al. Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors. Chin J Cancer. 2008;27(12):1302–6 (in Chinese).
Steiner H, Zangerl F, Stohr B, et al. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. J Urol. 2008;180:1348–52.
Hendry WF, Norman A, Nicholls J, et al. Abdominal relapse in stage 1 nonseminomatous germ cell tumours of the testis managed by surveillance or with adjuvant chemotherapy. BJU Int. 2000;86(1):89–93.
Ye YL, Sun XZ, Zheng FF, et al. Clinical analysis of management of pediatric testicular germ cell tumors. Urology. 2012;79(4):892–7.
Weir HK, Kreiger N, Marrett LD. Age at puberty and risk of testicular germ cell cancer (Ontario, Canada). Cancer Causes Control. 1998;9(3):253–8.
Fossa SD, Cvancarova M, Chen L, et al. Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. J Clin Oncol. 2011;29(8):963–70.
Herrinton LJ, Zhao W, Husson G. Management of cryptorchism and risk of testicular cancer. Am J Epidemiol. 2003;157(7):602–5.
McLachlan JA, Newbold RR, Burow ME, et al. From malformations to molecular mechanisms in the male: three decades of research on endocrine disruptors. APMIS. 2001;109(4):263–72.
Emmen JMA, McLuskey A, Adham IM, et al. Involvement of insulin-like factor 3 (Insl3) in diethylstilbestrol-induced cryptorchidism. Endocrinology. 2000;141(2):846–9.
Nef S, Shipman T, Parada LF. A molecular basis for estrogen induced cryptorchidism. Dev Biol. 2000;224(2):354–61.
Bouskine A, Nebout M, Mograbi B, et al. Estrogens promote human testicular germ cell cancer through a membrane-mediated activation of extracellular regulated kinase and protein kinase A. Endocrinology. 2008;149(2):565–73.
Ferlin A, Garolla A, Bettella A, et al. (2005) Androgen receptor gene CAG and GGC repeat lengths in cryptorchidism. Eur J Endocrinol. 2005;152(3):419–25.
Garolla A, Ferlin A, Vinanzi C, et al. Molecular analysis of the androgen receptor gene in testicular cancer. Endocr Relat Cancer. 2005;12(3):645–55.
Giwercman A, Lundin KB, Eberhard J, et al. Linkage between androgen receptor gene CAG trinucleotide repeat length and testicular germ cell cancer histological type and clinical stage. Eur J Cancer. 2004;40(14):2152–8.
Mackillop WJ, Zhang-Salomons J, Groome PA, et al. Socioeconomic status and cancer survival in Ontario. J Clin Oncol. 1997;15(4):1680–9.
Hoffman KE, Chen MH, Punglia RS, et al. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol. 2008;26(24):3937–42.
Conflict of interest
All authors declare that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dong, P., Liu, ZW., Li, XD. et al. Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors. Med Oncol 30, 494 (2013). https://doi.org/10.1007/s12032-013-0494-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-013-0494-y